Biogen's Q1 earnings exceed expectations, driven by Alzheimer's drug Leqembi sales, and plans to expand sales force and diversify.
Biogen reported Q1 earnings that beat expectations, with adjusted EPS of $3.67 and sales of $2.29 billion. The company's Alzheimer's drug, Leqembi, gained momentum, achieving sales of about $19 million. Biogen aims to increase its sales force as it targets 100,000 patients by 2026. The pharmaceutical company plans to diversify outside of neuroscience, focusing on business development in other areas to support its expensive, lengthy clinical trials.
April 24, 2024
18 Articles